early setting

Oncology

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

Oncology

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.